Sermorelin vs. HGH: What the Evidence Actually Shows

Almost every page comparing sermorelin to human growth hormone frames it as a choice between two similar products, one gentler than the other. That framing hides the single most important difference, which is not about mechanism or side effects at all: one of these has a current, in-force FDA label, and the other's approval was withdrawn. Recombinant human growth hormone is a prescription drug with an approved adult indication, an approved adult dose range, an adult adverse-reaction table, and adult body-composition trial results printed inside the label itself. Sermorelin has none of those, because the FDA approval it once held no longer exists.

That asymmetry runs through everything below, and this article does not smooth it over. It also does not pretend a head-to-head exists. A search of the published literature for a trial comparing sermorelin against recombinant GH on any outcome in adults returned nothing — the comparison here is made across two separate evidence bases, which is itself a finding worth stating up front.

The mechanism, in one paragraph

Recombinant human GH is the hormone. Injecting it replaces what the pituitary would have released, whether or not the pituitary can still release anything. Sermorelin is GHRH-(1-29), the first 29 amino acids of the hypothalamic signal that asks the pituitary to release GH. That difference has a practical consequence FDA states plainly in its own review of this drug class: growth-hormone secretagogues require residual pituitary function to work at all, while "hGH formulations replace endogenous GH itself, and thus are effective in patients with either absent or partially preserved pituitary function⁴." A secretagogue is a request; the hormone is the delivery. If the pituitary can't answer, the request goes nowhere.

What the FDA label for recombinant HGH actually says — the adult sections only

A word of caution before any number below, because it is the single most common error in writing about growth hormone: most of a somatropin label is about children. Norditropin's pediatric growth-hormone-deficiency dose is 0.17 to 0.24 mg/kg per week, and its other pediatric indications go as high as 0.47 mg/kg/week¹. Those are pediatric figures, in a per-week unit, for growth failure in children. They do not describe adult dosing, and quoting them as if they did inflates the adult numbers by an order of magnitude. Everything that follows comes from sections whose headings say "Adult."

The adult indication (§1.2). Norditropin is indicated in adults for exactly one thing: "the replacement of endogenous GH in adults with growth hormone deficiency (GHD)¹." Not age-related decline, not body recomposition, not performance. A diagnosed deficiency.

The adult dose (§2.3). Two regimens are permitted. Non-weight-based: initiate "with a dose of approximately 0.2 mg/day (range, 0.15 mg/day to 0.3 mg/day)" and increase every one to two months by roughly 0.1 to 0.2 mg/day, titrated "according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations," with the dose decreased if IGF-1 climbs above the age- and sex-specific normal range. Weight-based: initiate at "0.004 mg/kg daily" and increase to a maximum of "0.016 mg/kg daily," with the label's own caveat that this regimen is "Not recommended for obese patients as they are more likely to experience adverse reactions¹." Note what that is: a starting dose, a ceiling, a titration interval, and a lab value to titrate against. That entire apparatus is what a label provides and what sermorelin does not have.

What it did in adults (§14). The label publishes its own adult trial results. In a six-month, randomized, double-blind, placebo-controlled study in 31 adults with adult-onset GHD, dosed at 0.017 mg/kg/day capped at 1.33 mg/day, lean body mass rose by a treatment difference of 1.74 kg against placebo (95% CI 0.65 to 2.83, p=0.0028), and percent total body fat fell by a treatment difference of 4.74 percentage points (95% CI -7.18 to -2.30, p=0.0004)¹. Modest, real, measured, statistically significant, and published in the label of the drug that produced them.

What that costs, in the same label's own numbers

The adult adverse-reaction table is a separate, adult-only table, and it is not a gentle one.

Peripheral edema in 42% of adults on drug against 8% on placebo is the dominant signal, with edema, leg edema, myalgia, arthralgia and paresthesia trailing behind it — the classic fluid-retention picture of pharmacologic GH. Abnormal glucose tolerance appears in 6% versus 2%, and new type 2 diabetes mellitus in 5% versus 0%¹.

The contraindications are equally concrete. Norditropin must not be given in acute critical illness following open-heart surgery, abdominal surgery, multiple trauma or acute respiratory failure "due to the risk of increased mortality with use of pharmacologic doses of somatropin"; in active malignancy; in hypersensitivity; or in active proliferative or severe non-proliferative diabetic retinopathy¹. Its warnings section separately covers neoplasms, glucose intolerance, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism and pancreatitis¹. None of that is speculation about what GH might do — it is the sponsor's own required disclosure about what it does.

Sermorelin's side: the approval that no longer exists

Sermorelin was FDA-approved. It is not anymore. A DailyMed search returns zero results against a database published August 6, 2026, so there is no current label to read a dosage, warnings or adverse-reaction section from². openFDA's Drugs@FDA record explains why: both of Geref's applications — NDA 019863 and NDA 020443 — list every product as "Discontinued," each carrying FDA's own note that the product "was not discontinued or withdrawn for safety or effectiveness reasons³." A 2026 peer-reviewed review dates the corresponding approvals as withdrawn effective June 18, 2009, and reads FDA's note the same way this article does: it supports a commercial explanation rather than a new safety signal⁷.

That distinction matters and cuts both ways. Sermorelin was not pulled because it hurt anyone. It also is not currently an approved drug, which means nothing about a compounded sermorelin vial today — its identity, its concentration, its sterility — is covered by an FDA review of any kind. Our direct answer on whether sermorelin is safe works through that question in full, and our sermorelin dosage article covers the resulting dosing vacuum, so this article does not re-derive either.

The best adult sermorelin evidence that exists — and what it did not measure

Sermorelin's approval was pediatric. The trial behind it treated 110 previously untreated, prepubertal, growth-hormone-deficient children with 30 micrograms per kilogram once daily, subcutaneously, at bedtime, for up to a year⁵. That is a real trial, and it is about children with a diagnosed deficiency.

The strongest adult sermorelin evidence is a different study, and it is worth reading precisely because it is genuinely good and still does not show what the marketing implies. A randomized controlled trial at the National Institute on Aging gave ten healthy old men both a low (0.5 mg) and a high (1 mg) subcutaneous dose of GHRH-(1-29) twice daily for 14 days, with nine young men as a comparison group and 24-hour GH profiling before and during treatment⁶. The result was clean: at the high dose, mean 24-hour GH, area under peaks, peak amplitude and IGF-I all rose significantly, and "after high dose treatment, there were no significant differences in these parameters between age groups⁶." Fourteen days of sermorelin returned an old man's growth-hormone profile to a young man's. Fasting glucose, urinary C-peptide, blood pressure and chemistry panels were unaffected⁶.

Now read the study's own final sentence, because this is where the evidence stops and the marketing begins: the findings suggest "that prolonged treatment could improve age-related alterations in body composition⁶." Could. That is a hypothesis the authors offered for future work. The trial ran 14 days and measured hormones, not body composition — no lean mass, no fat mass, no strength, no function. Set that beside the growth-hormone label above, which publishes measured lean-mass and body-fat changes with confidence intervals and p-values from a six-month adult trial, and the shape of the comparison is clear. One side has an outcome. The other has a well-founded reason to expect one, still untested more than thirty years later.

The honest scoreboard

On mechanism, sermorelin has a real theoretical advantage that this article won't dismiss: because it works through the pituitary, GH release stays pulsatile and remains subject to the body's own feedback braking — somatostatin tone and IGF-1 negative feedback — in a way that injecting the hormone directly does not⁷. That is a genuine argument, and it is the reason a GHRH analog is not simply a weaker version of growth hormone.

But an argument is not an outcome. Recombinant GH has a current FDA label carrying an approved adult indication, an approved adult dose with a titration target, adult body-composition results with p-values, an adult adverse-reaction table, and a list of contraindications specific enough to name diabetic retinopathy by severity. Sermorelin has a withdrawn approval, one 14-day adult biomarker RCT, a pediatric pivotal trial, no controlled adult outcome data of any kind, and no trial that has ever compared it against the drug it is marketed as a gentler alternative to.

Both are banned in tested sport, year-round

This part is unambiguous on both sides and applies regardless of which one you are considering. WADA's 2026 Prohibited List puts growth hormone itself, its analogs and its fragments in section S2.2.3, and names sermorelin explicitly in section S2.2.4 among GHRH analogs. Both sit under a class heading that reads "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)," and the class is flagged "All prohibited substances in this class are non-Specified Substances⁸." There is no dose threshold, no in-competition-only window, and no version of this comparison in which one option is the compliant one. If you are tested under any WADA-code sport, both are positives.

The bottom line

Recombinant human growth hormone is a real, labeled, FDA-approved drug with a narrow adult indication — replacement in diagnosed adult growth-hormone deficiency — a defined dose range titrated against IGF-1, published adult trial results showing roughly 1.7 kg more lean mass and 4.7 percentage points less body fat than placebo over six months, and a labeled cost for that: edema in 42% of adults treated, new type 2 diabetes in 5%, and contraindications in active malignancy and critical illness. Sermorelin is a compounded GHRH analog whose own FDA approval was withdrawn in 2009 for commercial rather than safety reasons, whose best adult evidence is a 14-day trial that restored old men's hormone levels to young men's and explicitly did not measure body composition, and for which no trial has ever tested the comparison this article's title asks about. Both are prohibited in tested sport at all times. If sermorelin is the option you are actually weighing, our sermorelin provider rankings read each seller's own pharmacy and regulatory disclosures directly off their sites, and our comparisons against ipamorelin and against MK-677 cover the other two spokes of this cluster. For what the trials and the class's own labeled data report about sermorelin's side effects, our side-effect review and our article on the cancer question specifically are the companion reads.